Download Files:
MLN0905
SKU
HY-15155-1 mg
Category Reference compound
Tags Cancer, Cell Cycle/DNA Damage, Polo-like Kinase (PLK)
$85 – $970
Products Details
Product Description
– MLN0905 is a potent, orally active Polo-like kinase 1 (PLK1) inhibitor. MLN0905 has inhibitory potency against PLK1 with an IC50 value of 2 nM. MLN0905 can be used for the research of cancer[1][2].
Web ID
– HY-15155
Storage Temperature
– -20°C, 3 years; 4°C, 2 years (Powder)
Shipping
– Room Temperature
Applications
– Cancer-Kinase/protease
Molecular Formula
– C24H25F3N6S
References
– [1]Duffey MO, et al. Discovery of a potent and orally bioavailable benzolactam-derived inhibitor of Polo-like kinase 1 (MLN0905). J Med Chem. 2012 Jan 12;55(1):197-208.|[2]Shi JQ, et al. MLN0905, a small-molecule plk1 inhibitor, induces antitumor responses in human models of diffuse large B-cell lymphoma. Mol Cancer Ther. 2012 Sep;11(9):2045-53.
CAS Number
– 1228960-69-7
Molecular Weight
– 486.56
Compound Purity
– 99.94
SMILES
– CC1=NC=C(CCCN(C)C)C=C1NC2=NC(C(C=CC(C(F)(F)F)=C3)=C3NC(C4)=S)=C4C=N2
Clinical Information
– No Development Reported
Research Area
– Cancer
Solubility
– DMSO : ≥ 30 mg/mL
Target
– Polo-like Kinase (PLK)
Isoform
– PLK1
Pathway
– Cell Cycle/DNA Damage
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.